Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients

• DOI: 10.1111/j.1365-2893.2011.01473.x
• Publication Date: 2011-06-01T07:34:28Z
• Authors: A. Gramenzi; E. Loggi; L. Micco; C. Cursaro; S. Fiorino; S. Galli; S. Gitto; C. Galli; G. Furlini; M. Bernardi; P. Andreone
• Keywords: Hepatitis B; Hepatitis virus

Summary. Serum hepatitis B virus surface antigen (HBsAg) levels have been suggested to predict interferon response in chronic B. A few data are available on the role of HBsAg measurement nucleos(t)ide analogues (NA) treatment. We retrospectively investigated relation between changes and main treatment outcomes during long-term lamivudine e (HBeAg)-negative total 42 HBeAg-negative patients were consecutively enrolled an open-label study monotherapy (150 mg/die). quantified every 6 months by Architect assay (Abbott Diagnostics). HBV-DNA was quarterly real-time PCR (Roche The median duration 66 (20–153). One patient (2%) a primary nonresponder, 35 (83%) developed virological breakthrough (VB) remaining six (14%) classified as on-treatment responders. During treatment, decreased only responders, while no observed resistant patients. Failure achieve decrease 0.7 log10 IU/mL serum at month had positive predictive value developing VB 90% negative 100%. These high values also maintained subgroup for six. results this with small sample size suggest quantification management lamivudine-treated If validated prospectively larger cohort, measurements would be useful adjunct optimize antiviral therapy.